Ab­b­Vie taps Umo­ja for new in vi­vo CAR-T deal

Ab­b­Vie penned two deals with Umo­ja Bio­phar­ma for its in vi­vo CAR-T cell ther­a­py pro­grams, the com­pa­nies an­nounced Thurs­day.

Ab­b­Vie gets an op­tion to li­cense Umo­ja’s lead pro­gram, a CD19-di­rect­ed ther­a­py for blood can­cers, un­der the first agree­ment. Un­der the sec­ond deal, the two com­pa­nies will de­vel­op up to four in vi­vo CAR-T ther­a­py can­di­dates for tar­gets cho­sen by Ab­b­Vie.

Umo­ja re­ceived up­front pay­ments and an eq­ui­ty in­vest­ment from Ab­b­Vie, though it de­clined to share specifics. With both deals added up, Umo­ja could re­ceive up to $1.44 bil­lion in mile­stones, plus sales mile­stones and roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER